Shares of Davita Inc (NYSE:DVA) ended Friday session in green amid volatile trading. The shares closed up +0.37 points or 0.58% at $64.44 with 2,480,597 shares getting traded. Post opening the session at $63.95, the shares hit an intraday low of $63.57 and an intraday high of $64.56 and the price vacillated in this range throughout the day. The company has a market cap of $13.41 billion and the numbers of outstanding shares have been calculated to be 206.90 million shares.
Davita Inc (DVA) on Sept. 14, 2016 announced that Craig Albright will lead its medical group operations at JSA Healthcare, a division of DaVita Inc. operating in Florida, as market president.
“We are excited to welcome Craig to the team and are confident that his breadth of experience in various health care sectors will bring immense value to our organization,” said Joe Mello, chief operating officer for DaVita’s medical groups. “His 20 years of health care leadership experience aligns with our dedication to service excellence and quality care.”
Prior to joining DaVita, Albright served as executive vice president at Healogics, Inc., and was responsible for marketing, corporate strategy, government affairs and local market growth. In addition, he has served in chief executive officer and corporate venture growth roles in many other prestigious health care companies.
Albright has also served as a strategic advisor to a number of widely recognized and successful organizations, including the Cleveland Clinic Foundation; CardioNet Inc.; Patient Safe Solutions, Inc. and OneRecovery, Inc.
“I’m looking forward to joining the DaVita and JSA Healthcare team in order to help expand and drive growth in the Florida market,” said Albright. “Their integrated care model is right at the heart of innovation necessary to address how medical groups and provider networks are changing and I’m excited to join an organization whose mission and proven clinical expertise are so well aligned with the future of health care.”
Shares of ResMed Inc. (NYSE:RMD) ended Friday session in red amid volatile trading. The shares closed down -0.50 points or -0.77% at $64.46 with 2,466,001 shares getting traded. Post opening the session at $65.02, the shares hit an intraday low of $64.21 and an intraday high of $65.09 and the price vacillated in this range throughout the day. The company has a market cap of $9.00 billion and the numbers of outstanding shares have been calculated to be 140.70 million shares.
ResMed Inc. (RMD) on Sept. 6, 2016 welcomed positive results from a multicenter, randomized controlled trial known as HOT-HMV.
The HOT-HMV trial studied COPD patients who were hypercapnic, that is, had high carbon dioxide levels in their blood, and who were hospitalized after their COPD worsened. The study assessed whether adding home non-invasive ventilation to home oxygen therapy could improve the length of time these patients went without dying or being re-admitted to the hospital.
COPD is a collection of lung diseases including chronic bronchitis and emphysema. It is a progressive, fatal condition that is one of the leading causes of death worldwide. The United States Centers for Disease Control estimates that COPD costs the United States $36 billion dollars in direct and indirect costs.
Patients in the study who received at home non-invasive ventilation in addition to oxygen therapy had a 51 percent decreased risk of re-hospitalization or death, compared to those who received oxygen therapy alone. (These results were based on a hazard ratio of = 0.49, 95 percent confidence interval = (0.31, 0.77) p=0.002).
Patients who received home non-invasive ventilation at home went a median of 4.3 months without dying or being admitted to the hospital, compared to 1.4 months for those who did not receive non-invasive ventilation.
“These study results add further weight to the existing evidence supporting the broader use of non-invasive ventilation for patients living with COPD. The results strengthen arguments for a pivotal study in the area,” said ResMed chief medical officer, Glenn Richards, M.D.
“In particular, the results are important because they show giving patients with hypercapnic COPD a non-invasive ventilation device for use in the home can very significantly cut their risk of re-hospitalization and death after an acute worsening of the disease.”